Genedrive (GB:GDR) has released an update.
Genedrive PLC has announced a significant milestone in the DEVOTE programme for its CYP2C19-ID kit, now meeting patient numbers for CE-IVD certification anticipated in early 2025. The point-of-care genetic test, which identifies genetic variants affecting drug response, has outperformed reference laboratory tests in accuracy and breadth of variant coverage. The test, which has UKCA certification and is under review by NICE, offers rapid results in emergency care settings, improving treatment plans for patients with certain genetic profiles.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.
